The therapeutic potential of GPR119 agonists for type 2 diabetes

Bibliography

• Haffner SM, Lehto S, Ronnemaa T, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
   PubMed Web of Science ®Google Scholar
• Davis MD. Diabetic retinopathy. A clinical overview. Diabetes Care 1992;15:1844-74
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15(3):318-68
   PubMed Web of Science ®Google Scholar
• Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994;43(6):735-40
   PubMed Web of Science ®Google Scholar
• Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004;53:S16-21
   PubMed Web of Science ®Google Scholar
• Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 2007;23(4):933-44
   PubMed Web of Science ®Google Scholar
• Lupi R, Del Guerra S, Fierabracci V, Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(Suppl 1):S134-7
   PubMed Web of Science ®Google Scholar
• Stephenson J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA 2011;306(2):143
   PubMed Web of Science ®Google Scholar
• Briefing document: July 13-14, 2010 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. FDA. Washington, DC, 2010. Available from: www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm191113.htm [Last accessed 1 November 2011]
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Tourrel C, Bailbe D, Meile MJ, Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50(7):1562-70
   PubMed Web of Science ®Google Scholar
• Ross SA, Ekoe JM. Incretin agents in type 2 diabetes. Can Fam Physician 2010;56(7):639-48
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Hoglund PJ, Gloriam DEI, Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003;554:381-8
   PubMed Web of Science ®Google Scholar
• Ohishi T, Takasaki J, Matsumoto M, Method of screening remedy for diabetes. WO2002044362; 2002
   Google Scholar
• Bonini JA, Borowsky BE, Adham N, DNA encoding SNORF25 receptor. US6221660B1; 2002
   Google Scholar
• Bonini JA, Borowsky BE, Adham N, Methods of identifying compounds that bind to SNORF25 receptors. US6468756B1; 2002
   Google Scholar
• Jones RM, Semple G, Fioravanti B, 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycaemia. WO2004065380; 2004
   Google Scholar
• Takeda S, Kadowaki S, Haga T, Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 2002;520:97-101
   PubMed Web of Science ®Google Scholar
• Davey J. G-protein-coupled receptors: new approaches to maximise the impact of GPCRs in drug discovery. Expert Opin Ther Targets 2004;8:165-70
   PubMed Web of Science ®Google Scholar
• Griffin G. Methods for identification of modulators of OSGPR116 activity. US7083933B1; 2006
   Google Scholar
• Chu ZL, Jones RM, He H, A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148:2601-9
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, Deorphanization of a G-protein coupled receptor for oleoylethanolamide and its use in the discovery of small molecule hypophagic agents. Cell Metab 2006;3:167-75
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Inoue H, Kawakami S, Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP cells. Biochem Biophys Res Commun 2006;351:474-80
   PubMed Web of Science ®Google Scholar
• Soga T, Ohishi T, Matsui T, Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein coupled receptor. Biochem Biophys Res Commun 2005;326:744-51
   PubMed Web of Science ®Google Scholar
• Chu Z-L, Leonard JN, Al-Shamma HA, Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level. WO2006076231; 2006
   Google Scholar
• Fyfe M, Overton H, White J, Discovery of novel, orally active, synthetic GPR119 agonists as potential agents for treatment of obesity and associated metabolic disorders. Diabetes 2006;55(Suppl 1):346
   Google Scholar
• Fyfe M, White J, Widdowson P, GPR119 agonists are potential novel oral agents for the treatment of diabesity. Diabetes 2007;56(Suppl 1):532
   Google Scholar
• Drucker DJ, Jin T, Asa SL, Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enterondocrine cell line. Mol Endocrinol 1994;8:1646-55
   PubMed Web of Science ®Google Scholar
• Chu Z, Carroll C, Alfonso J, A role for intestinal endocrine cell-expressed GPR119 in glycemic control by enhancing GLP-1 and GIP release. Endocrinology 2008;149:2038-47
   PubMed Web of Science ®Google Scholar
• Ning Y, O'Neill K, Lan H, Endogenous and synthetic agonists of GPR119 differ in signaling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 2008;155:1056-65
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohishi T, Matsui T, Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2010;400(3):437-41
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohishi T, Matsui T, The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic beta-cell function. Diabetes Obes Metab 2011;13(1):34-41
   PubMed Web of Science ®Google Scholar
• Yoshida S, Ohishi T, Matsui T, Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochem Biophys Res Commun 2010;402(2):280-5
   PubMed Web of Science ®Google Scholar
• Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64(12):1339-58
   PubMed Web of Science ®Google Scholar
• Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 1989;18(1):163-83
   PubMed Web of Science ®Google Scholar
• Ohishi T, Koizumi T. Method of screening insulin content enhancer. WO2004024943; 2004
   Google Scholar
• Yoshida S, Tanaka H, Oshima H, AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 2010;400(4):745-51
   PubMed Web of Science ®Google Scholar
• Cissell MA, Zhao L, Sussel L, Transcription factor occupancy of the insulin gene in vivo. Evidence for direct regulation by Nkx 2.2. J Biol Chem 2003;278:751-6
   PubMed Web of Science ®Google Scholar
• Habener JF, Kemp DM, Thomas MK. Minireview: transcriptional regulation in pancreatic development. Endocrinology 2005;146(3):1025-34
   PubMed Web of Science ®Google Scholar
• Gefen-Halevi S, Rachmut IH, Molakandov K, NKX6.1 promotes PDX-1-induced liver to pancreatic beta-cells reprogramming. Cell Reprogram 2010;12(6):655-64
   PubMed Web of Science ®Google Scholar
• Inoue H, Rudnick A, German MS, Isolation, characterization, and chromosomal mapping of the human Nkx6.1 gene (NKX6A), a new pancreatic islet homeobox gene. Genomics 1997;40(2):367-70
   PubMed Web of Science ®Google Scholar
• Perfetti R, Zhou J, Doyle ME, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141(12):4600-5
   PubMed Web of Science ®Google Scholar
• Cerf ME. Transcription factors regulating beta-cell function. Eur J Endocrinol 2006;155:671-9
   PubMed Web of Science ®Google Scholar
• Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians 1998;110(1):12-21
   PubMedGoogle Scholar
• Gu C, Stein GH, Pan N, Pancreatic beta cells require NeuroD to achieve and maintain functional maturity. Cell Metab 2010;11(4):298-310
   PubMed Web of Science ®Google Scholar
• Kaneto H, Matsuoka TA, Katakami N, Combination of MafA, PDX-1 and NeuroD is a useful tool to efficiently induce insulin-producing surrogate beta-cells. Curr Med Chem 2009;16(24):3144-51
   PubMed Web of Science ®Google Scholar
• Steiner DF, James DE. Cellular and molecular biology of the beta cell. Diabetologia 1992;35(Suppl 2):S41-8
   PubMed Web of Science ®Google Scholar
• Schuppin GT, Rhodes CJ. Specific co-ordinated regulation of PC3 and PC2 gene expression with that of preproinsulin in insulin-producing beta TC3 cells. Biochem J 1996;313:259-68
   PubMed Web of Science ®Google Scholar
• Chu ZL, Carroll C, Alfonso J, A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008;149(5):2038-47
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318(2-3):429-35
   PubMed Web of Science ®Google Scholar
• Vahl TP, Paty BW, Fuller BD, Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003;88(4):1772-9
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3(3):167-75
   PubMed Web of Science ®Google Scholar
• Semple G, Fioravanti B, Pereira G, Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 2008;51(17):5172-5
   PubMed Web of Science ®Google Scholar
• Wu Y, Kuntz JD, Carpenter AJ, 2,5-Disubstituted pyridines as potent GPR119 agonists. Bioorg Med Chem Lett 2010;20(8):2577-81
   PubMed Web of Science ®Google Scholar
• Szewczyk JW, Acton J, Adams AD, Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett 2010; published online 22 December 2010; doi:10.1016/j.bmcl.2010.12.086
   Google Scholar
• Mascitti V, Stevens BD, Choi C, Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. Bioorg Med Chem Lett 2011;21(5):1306-9
   PubMed Web of Science ®Google Scholar
• Nunez DJ, Bush MA, Collins DA, Evaluation of GSK-1292263, a Novel GPR-119 Agonist, in Type 2 Diabetes Mellitus (T2DM): Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses. American Diabetes Association – 71st Meeting; San Diego; 2011
   Google Scholar
• Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes. PRNewswire. San Diego, 2010. Available from: http://invest.arenapharm.com/releasedetail.cfm?releaseid=527328 [Last accessed 1 November 2011]
   Google Scholar
• Roberts B, Gregoire FM, Karpf DB, MBX-2982, a Novel Oral GPR119 Agonist for the Treatment of Type 2 Diabetes: Results of Single & Multiple Dose Studies. American Diabetes Association – 69th Meeting; New Orleans; 2009
   Google Scholar
• Sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011. PRNewswire. Paris, 2011. Available from: http://www.prnewswire.com/news-releases/sanofi-aventis-strong-performance-of-growth-platforms-in-q1-2011-120852319.html [Last accessed 1 November 2011]
   Google Scholar
• Astrup A, Rossner S, Van Gaal L, NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
   PubMed Web of Science ®Google Scholar
• Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition 2010;26:243-9
   PubMed Web of Science ®Google Scholar
• Madsen AN, Hansen G, Paulsen SJ, Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 2010;206:287-96
   PubMed Web of Science ®Google Scholar
• Ruttimann EB, Arnold M, Hillebrand JJ, Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009;150:1174-81
   PubMed Web of Science ®Google Scholar
• Thum T, Anker SD. Liraglutide for weight loss in obese people. Lancet 2010;375:551-2
   PubMedGoogle Scholar
• Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007;293:R983-7
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24(1):275-86
   PubMed Web of Science ®Google Scholar
• Wyne KL. Free fatty acids and type 2 diabetes mellitus. Am J Med 2003;115(Suppl 8A):29S-36S
   PubMedGoogle Scholar
• Ladriere L, Igoillo-Esteve M, Cunha DA, Enhanced signaling downstream of ribonucleic Acid-activated protein kinase-like endoplasmic reticulum kinase potentiates lipotoxic endoplasmic reticulum stress in human islets. J Clin Endocrinol Metab 2010;95(3):1442-9
   PubMed Web of Science ®Google Scholar